Loading stock data…
MYO
$0.90+0.04 (+4.68%)
Market ClosedLast close May 1
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Myomo, Inc. in the Healthcare sector is trading at $0.90. The stock is currently near its 52-week low of $0.60, remaining 9.1% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why MYO maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.90
Potential Upside
5%
Whystock Fair Value$0.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled up...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-98.98%
Volume
Today's trading volume
331,674
Recent News
Elevance Expands Myomo Coverage To Support Tech Enabled Care Narrative
Elevance Health (NYSE:ELV) entered into new network participation agreements with Myomo. The agreements expand coverage for advanced orthotic devices to tens of millions of Elevance members. Coverage spans commercial, Medicare Advantage, and Medicaid plans, adding to Elevance's technology-enabled care offerings. For you as an investor, this move speaks directly to how Elevance Health is shaping its core health benefits business around technology-enabled, patient-centered care. The Myomo...
Myomo Inc (MYO) Q4 2025 Earnings Call Highlights: Record Revenue Amid Rising Expenses and ...
Despite achieving its highest revenue quarter, Myomo Inc (MYO) faces increased operating losses and outlines strategic initiatives for future growth.
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Beats Revenue Estimates
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +14.16% and +0.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Myomo Inc (MYO) Q3 2025 Earnings Call Highlights: Strong International Growth Amidst Domestic ...
Myomo Inc (MYO) reports robust revenue growth in Germany, but faces domestic hurdles with decreased margins and increased operating expenses.